What Is RMAT Designation, and How Does It Speed Up Stem Cell Therapy Approval?

If you've read a press release announcing that a stem cell therapy "received RMAT designation from the FDA," it's easy to assume the product has been approved, or is close to it. It hasn't — and understanding why matters. RMAT (Regenerative Medicine Advanced Therapy) designation is a real, legally defined FDA program that fast-tracks the development of promising cell and tissue-based therapies. It does not mean a product is safe, effective, or approved. This article explains what RMAT actually is, where it came from, who qualifies, what it does (and doesn't) get a company, and how to read an "RMAT designation" headline without overestimating what it means for patients.

What RMAT Is, and Where It Came From

RMAT designation was created by Section 3033 of the 21st Century Cures Act, a sweeping piece of federal legislation signed into law on December 13, 2016. Among many other provisions, the Cures Act directed the FDA to establish an expedited program specifically for regenerative medicine products — a category that didn't fit neatly into the agency's existing fast-track tools, which were built mostly around conventional drugs. The FDA's Center for Biologics Evaluation and Research (CBER), which oversees cell and gene therapies, administers the program. In FDA's own description, RMAT is meant to work like the agency's Breakthrough Therapy designation, but tailored to the unique science and manufacturing realities of cell therapies, tissue-engineered products, and certain gene therapies.

Who Qualifies: The Eligibility Test

To receive RMAT designation, a product must satisfy three conditions, all defined by the FDA. First, it must be a qualifying product type: a cell therapy, a therapeutic tissue-engineering product, a human cell and tissue product, certain gene therapies, or a combination product that uses one of these. Second, it must be intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition. Third — and this is the criterion companies most often stumble on — there must be "preliminary clinical evidence" indicating the product has the potential to address an unmet medical need. That third bar is deliberately lower than what's required for approval; it can be satisfied with early-phase or even small, uncontrolled clinical data. But it is not nothing. FDA's own cumulative statistics show the agency denies a substantial share of RMAT requests: across fiscal years 2017 through 2025, the FDA received 388 RMAT designation requests and granted 193 of them — roughly half. Grant rates have improved markedly in the most recent two fiscal years (43 of 59 requests granted in FY2024, and 50 of 91 in FY2025), but this is not a designation that's handed out automatically.

What RMAT Designation Actually Gets You

Once granted, RMAT designation gives a sponsor several concrete regulatory advantages. It includes all the benefits of the FDA's Fast Track program, notably rolling review, meaning a company can submit completed portions of its marketing application as they're ready rather than waiting for the entire package. It opens the door to more frequent, earlier, and more substantive meetings with FDA reviewers, including discussions about what surrogate or intermediate endpoints might be acceptable for approval. It makes a product potentially eligible for priority review once an application is filed, and — often the most consequential benefit — potential eligibility for accelerated approval, which can allow approval based on a surrogate or intermediate endpoint reasonably likely to predict clinical benefit, or on data from a limited number of trial sites rather than large multicenter studies. FDA guidance also allows post-approval confirmatory evidence to draw on sources like patient registries or electronic health records, which can be especially useful for the small patient populations typical of rare-disease cell therapies.

RMAT vs. FDA Approval: The Line That Matters

This is the part patients and caregivers most need to understand clearly: RMAT designation is not approval, and it is not proof that a therapy works. The FDA states this explicitly in its own guidance: "RMAT designation is not the same as an approval and does not change the statutory standards for demonstration of safety and effectiveness needed for marketing approval." In practice, that means a designated product still has to go through the same rigorous clinical trial process, and still has to convince FDA reviewers that its benefits outweigh its risks, before it can be marketed and sold. Designation changes the process — how fast a company can move, how much interaction it gets with regulators, what kind of evidence might eventually support approval — not the ultimate scientific bar. Many RMAT-designated products are eventually denied approval, withdrawn, or discontinued after further study; designation is a vote of interest and priority, not a guarantee of a future product.

Real Examples: Stem Cell Products That Have Received RMAT Designation

The clearest illustration of both sides of this story comes from actual designated products. Casgevy (exagamglogene autotemcel) and Lyfgenia (lovotibeglogene autotemcel), both approved by the FDA on December 8, 2023 for sickle cell disease, are built on a patient's own gene-modified hematopoietic (blood-forming) stem cells; both received RMAT designation during development before their eventual approval — a case where the pathway worked as designed. On the other side sits Mesoblast's rexlemestrocel-L (marketed as Revascor once approved), an allogeneic mesenchymal stem cell product derived from donor bone marrow. It received RMAT designation for chronic low back pain in February 2023 and a second RMAT designation for pediatric congenital heart disease in December 2024 — years after its first designation — and as of this writing remains investigational for both indications, not yet FDA-approved. That gap is the point: designation can precede approval by years, or may never lead to it at all.

What Happens After Designation

After receiving RMAT status, a sponsor typically works with FDA through a series of scheduled meetings to map out its remaining trials, discuss what endpoints might support accelerated approval, and plan its eventual Biologics License Application (BLA). The company still has to run the clinical trials, generate the safety and efficacy data, and file for approval — RMAT just changes the conversation and, often, the timeline around that process. FDA can also decide to rescind a designation if a product no longer meets the criteria as data accumulate.

Why This Matters for Patients

If you're evaluating a stem cell clinic, company, or clinical trial and see "RMAT designation" mentioned, treat it as a meaningful but limited signal: it tells you the FDA found the early data promising enough to grant expedited attention, not that the therapy has been shown to work or is available for general use outside of a clinical trial. It is a genuinely encouraging marker — a sign that a promising idea is getting real regulatory traction and that the system built to move it forward is functioning as intended — but it sits well short of the finish line. The clearest way to check whether a product is actually approved is to look for it in FDA's own approvals database, not to rely on a designation announcement alone.

Bottom Line

RMAT designation is a real, useful FDA tool created by the 21st Century Cures Act to help promising regenerative medicine products — including many stem cell therapies — move through development faster, with more FDA guidance and potentially lighter evidentiary requirements for eventual approval. It is not approval, and it does not certify that a product is safe or effective. Some RMAT-designated stem cell therapies, like Casgevy and Lyfgenia, have gone on to full approval; others, like rexlemestrocel-L, remain in years-long development after designation. Understanding that distinction is one of the most important things a patient can know before deciding what "FDA-recognized" actually means for a regenerative therapy.